Rajiv Patni
Director/Board Member chez QUINCE THERAPEUTICS, INC.
Profil
Rajiv Patni is currently working as a Director at Quince Therapeutics, Inc. He previously held positions as an Executive Director & Vice President at Roche Pharmaceuticals, Inc., a Senior Medical Director at Novartis Pharmaceuticals Corp., a Senior Medical Director at Pfizer Pharmaceuticals, Inc., and a Chief Medical Officer & Executive Vice President at Portola Pharmaceuticals LLC.
In addition, he served as an Executive VP, Chief Research & Development Officer at Reata Pharmaceuticals, Inc. in 2023, as well as the Chief Medical Officer at Adamas Pharmaceuticals LLC from 2015 to 2020, the Chief Development Officer at OCERA Therapeutics LLC from 2014 to 2015, and the Chief Medical Officer at Actelion Pharmaceuticals US, Inc. from 2007 to 2014.
Dr. Patni obtained a doctorate degree from the Icahn School of Medicine at Mount Sinai and an undergraduate degree from The Sophie Davis School of Biomedical Education.
Postes actifs de Rajiv Patni
| Sociétés | Poste | Début |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Director/Board Member | 15/02/2024 |
Anciens postes connus de Rajiv Patni
| Sociétés | Poste | Fin |
|---|---|---|
| REATA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 26/09/2023 |
| ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 15/02/2020 |
| OCERA THERAPEUTICS INC | Corporate Officer/Principal | 01/06/2015 |
Actelion Pharmaceuticals US, Inc.
 Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
| PORTOLA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Rajiv Patni
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
| The Sophie Davis School of Biomedical Education | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| QUINCE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | Health Technology |
